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Abstract
Aberrant transforming growth factor–β (TGF-β) signaling is a hallmark of the stromal microenvironment in cancer.
Dickkopf-3 (Dkk-3), shown to inhibit TGF-β signaling, is downregulated in prostate cancer and upregulated in the stroma in
benign prostatic hyperplasia, but the function of stromal Dkk-3 is unclear. Here we show that DKK3 silencing in WPMY-1
prostate stromal cells increases TGF-β signaling activity and that stromal cell-conditioned media inhibit prostate cancer cell
invasion in a Dkk-3-dependent manner. DKK3 silencing increased the level of the cell-adhesion regulator TGF-β–induced
protein (TGFBI) in stromal and epithelial cell-conditioned media, and recombinant TGFBI increased prostate cancer cell
invasion. Reduced expression of Dkk-3 in patient tumors was associated with increased expression of TGFBI. DKK3
silencing reduced the level of extracellular matrix protein-1 (ECM-1) in prostate stromal cell-conditioned media but
increased it in epithelial cell-conditioned media, and recombinant ECM-1 inhibited TGFBI-induced prostate cancer cell
invasion. Increased ECM1 and DKK3 mRNA expression in prostate tumors was associated with increased relapse-free
survival. These observations are consistent with a model in which the loss of Dkk-3 in prostate cancer leads to increased
secretion of TGFBI and ECM-1, which have tumor-promoting and tumor-protective roles, respectively. Determining how
the balance between the opposing roles of extracellular factors inﬂuences prostate carcinogenesis will be key to developing
therapies that target the tumor microenvironment.
Introduction
Signals from cancer cells convert benign stroma to cancer
stroma, creating an environment that facilitates tumor pro-
gression [1]. However, the tumor microenvironment also
contains proteins that can improve patient prognosis [2].
Dickkopf-3 (Dkk-3) is a secreted glycoprotein that is
downregulated in prostate cancer [3–6]. Prostate glands of
Dkk3 mutant mice exhibit changes in prostate tissue orga-
nization and increased prostate epithelial cell proliferation,
suggesting that Dkk-3 is required to maintain a normal
microenvironment and that its loss could play a role in
cancer progression [4, 7]. In addition, ectopic expression of
Dkk-3 inhibits prostate cancer cell proliferation and inva-
sion [4, 7], and an adenoviral vector expressing Dkk-3, Ad-
REIC, has shown promise as a therapy for prostate cancer in
early stage trials [8, 9]. Dkk-3 is also expressed in prostate
stroma, with increased levels reported in benign prostatic
hyperplasia (BPH) and prostate cancer [6]. Knockdown of
Dkk-3 in primary prostate smooth muscle cells reduces their
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proliferation and differentiation [10]. However, it is not
known if stromal Dkk-3 plays a protective or tumor-
promoting role in prostate disease. In addition, Dkk-3 is
upregulated in the tumor endothelium, suggesting it plays a
role in angiogenesis [11–13].
Knockdown of DKK3 in prostate epithelial cells disrupts
their ability to form acini in 3D cultures, and this can be
rescued by inhibition of TGF-β/Smad signaling [7]. TGF-β
signaling plays an important role in prostate tissue home-
ostasis [1], and its aberrant activation leads to expression of
pro-invasive factors, such as matrix metalloproteases
(MMPs) [14]. Notably, Dkk-3 inhibits MMP expression and
activity, and MMP inhibitors rescue the effects of DKK3
knockdown on prostate epithelial cell acinar morphogenesis
[15]. Based on these studies, we have proposed that endo-
genous Dkk-3 plays a protective role in prostate cancer by
limiting TGF-β/Smad/MMP signaling [16]. However, the
loss of Dkk-3 is anticipated to have effects on the activity
and/or expression of other proteins in the tumor micro-
environment. In this study, we show that the expression
level of stromal Dkk-3 is also relevant to prostate cancer,
and we identify two secreted proteins, TGFBI (Transform-
ing Growth Factor Beta Induced) and ECM-1 (extracellular
matrix protein 1), whose levels are differentially affected by
DKK3 silencing in prostate stromal cells and that appear to
play opposing roles in prostate cancer.
Fig. 1 Reduced levels of Dkk-3
in prostate cancer and prostate
cancer stroma. a Prostate
sections from the same patient
containing benign (top) or tumor
(bottom) tissue were stained for
Dkk-3, smooth muscle actin
(SMA), hematoxylin and eosin
(H&E) and epithelial
cytokeratins (CK). b Higher
magniﬁcation images for Dkk-3
staining; arrows indicate Dkk-3
in epithelial (red), stromal
(green), and endothelial (blue)
cells; scale bars 112 µm. c
Statistical analysis of Dkk-3
expression; Gl Gleason, PCaE
prostate cancer epithelium, BS
benign stroma, PCaS prostate
cancer stroma, BE benign
epithelium; p values from Chi
square, Yates correction, and/or
Fisher’s Exact test, two-sided
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Results
Reduced expression of Dkk-3 in prostate cancer
stroma
Dkk-3 is abundant in the normal prostate epithelium and
downregulated in prostate cancer [3, 4, 6]. Changes in the
expression of Dkk-3 have also been reported in benign
prostatic hyperplasia [10], but less is known about the
expression of Dkk-3 in cancer stroma. We used immuno-
histochemistry to compare Dkk-3 levels in epithelial and
stromal cells in cancer and benign tissue from 99 treatment-
naive prostate cancer patients (Supplementary Table 3).
Dkk-3 levels in stromal and epithelial cells were scored
independently to account for lower expression levels in
prostate stroma (Supplementary Figure 1). Near-adjacent
sections were stained for smooth muscle actin and vimentin
to detect reactive stroma [17] and with pan cytokeratin
antibodies to detect epithelial/cancer cells. An example of a
patient with moderate Dkk-3 expression in benign epithe-
lium and low Dkk-3 expression in tumor epithelium and
tumor stroma, with some expression in endothelial cells is
shown in (Fig. 1a, b). Statistical analysis indicated that Dkk-
3 expression was not only lower in tumor epithelium than in
benign epithelium, but was also lower in tumor stroma than
in benign stroma (Fig. 1c).
DKK3 gene silencing increases of TGF-β signaling in
prostate stromal cells
To investigate the function of stromal Dkk-3, we used the
prostate stromal cell line WPMY-1, which is derived from
the benign prostate of the same donor as RWPE-1 prostate
epithelial cells and has been used as a model to investigate
communication between prostate stromal cells and prostate
epithelial and prostate cancer cells [18, 19]. WPMY-1 cell
lines stably expressing DKK3 shRNA (WPMY-1 shDKK3
Wsh7 and Wsh8) and control shRNA (WPMY-1 shCTRL
PSM2, PSM3, NPSM) were generated. Q-PCR conﬁrmed
downregulation of DKK3 mRNA (Fig. 2a). Dkk-3 in cell
extracts was approximately 10-fold less abundant in
shDKK3 cells than in parental and shCTRL cells (Fig. 2b,
c) and 3.5-fold (Wsh7 cells) to 10-fold (Wsh8 cells) less
abundant in shDKK3 cell cell-conditioned media (CM) than
in parental and shCTRL cell CM (Fig. 2d, e and Supple-
mentary Figure 2a). DKK3 silencing did not affect WPMY-
1 cell proliferation (Supplementary Figure 2b).
Given the effects of Dkk-3 on TGF-β signaling [7] and
the importance of TGF-β signaling in stromal cell differ-
entiation [1], we determined the effect of DKK3 silencing
on TGF-β signaling in WPMY-1 cells. TGF-β/Smad-
dependent gene reporter activity was higher in DKK3-
silenced cells than in control cells (Fig. 2f) and was strongly
reduced by the TGFBR1 inhibitors SB431542 and
SB525334 (Fig. 2g). A signiﬁcant effect was observed for
10 nM SB525334, consistent with inhibition of TGFBR1/
ALK5 (IC50 14 nM), rather than ALK4/7 (IC50 59 nM). In
addition, DKK3-silenced cells had higher levels of phos-
phorylated Smad3 and a trend for higher levels of Smad3
(Fig. 2h–k), whereas Smad2 and Smad4 were not affected
(Supplementary Figure 3). In contrast to what has been
observed in primary prostate stromal cells [10, 15], TGF-β
and DKK3-silencing did not signiﬁcantly affect MMP2 and
SMA expression in WPMY-1 cells, although there was a
trend for increased MMP2 levels in CM from DKK3-
silenced cells (Supplementary Figure 4). However, TGF-β
increased the levels of Dkk-3 in WPMY-1 CM (Fig. 2l, m).
In summary, DKK3 silencing increases autocrine TGF-β/
Smad3 signaling in WPMY-1 cells but has limited effects
on TGF-β induction of MMP2 and SMA, possibly because
TGF-β increases Dkk-3 secretion.
Contrasting effects of DKK3 gene silencing on gene
expression in prostate stromal and epithelial cells
Activation of TGF-β signaling in WPMY-1 cells and
RWPE-1 cells is accompanied by changes in Smad3 and
Fig. 2 DKK3 gene silencing increases TGF-β signaling in prostate
stromal cells. a q-RT-PCR analysis showing average relative expres-
sion of DKK3 mRNA in shCTRL (PSM2/PSM3) and shDKK3 (Wsh8/
Wsh7) cells; *p < 0.001 by Student’s t test. b Western blots of extracts
from parental, shCTRL (PSM2, NPSM), and shDKK3 (Wsh7 and
Wsh8) WPMY-1 cells probed for Dkk-3 and GAPDH; the position of
Dkk-3 is indicated. c Densitometry analysis of Dkk-3 normalized to
GAPDH, error bars show standard deviation (SD), n= 7, *p < 0.01
compared to WPMY-1. d Western blots of conditioned media (CM)
from the indicated cell lines were probed for Dkk-3; the position of
secreted Dkk-3 is indicated GAPDH in cell extracts was used as a
loading control. e Densitometry analysis of Dkk-3 in CM normalized
to GAPDH in extracts; error bars represent SD, n= 4, *p < 0.0001
compared to WPMY-1. f Gene reporter assays for shCTRL (PSM2,
NPSM) and shDKK3 (Wsh7, Wsh8) WPMY-1 cells transfected with
CAGA-Luc and renilla; error bars show SD, n= 3, *p < 0.01, com-
pared to shCTRL PSM2. Graph shows average CAGA-luc/renilla
ratios normalized to untreated PSM2 control cells, error bars show SD,
n= 3, *p < 0.05. g Gene reporter assays for shCTRL (PSM3) and
shDKK3 (Wsh8) WPMY-1 cells transfected with CAGA-Luc and
renilla and treated with vehicle (DMSO) or the indicated concentra-
tions of the TGFBR1 inhibitors SB431542 and SB525334; error bars
show SD, n= 3 (100 nM), n= 6 (10 nM), *p < 0.05 compared to
DMSO in each cell line. h Western blots of extracts from shCTRL
(PSM2) and shDKK3 (Wsh7, Wsh8) WPMY-1 cells cultured for 24 h
with (+) or without (−) 10 ng/ml TGF-β1 probed for pSmad3 and
GAPDH. i Densitometry analysis of pSmad3 normalized to GAPDH;
n= 4, *p < 0.05. jWestern blots of extracts from shCTRL (PSM2) and
shDKK3 (Wsh8) WPMY-1 cells cultured as in h probed for Smad3
and GAPDH. k Densitometry analysis of Smad3 normalized to
GAPDH; n= 4. l Western blots of extracts and CM from parental and
shDKK3 (Wsh8) WPMY-1 cells as in h probed for Dkk-3 and
GAPDH. m Densitometry analysis of Dkk-3 in CM, normalized to
GAPDH in extracts; n= 7, *p < 0.05
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Smad2 [15], respectively, suggesting there may be cell-
type-speciﬁc differences in the response to Dkk-3. To study
this further, we examined the expression of genes reported
to be affected by Dkk-3. These included genes down-
regulated (ACTG2) and upregulated (ANGPT1) by
DKK3 silencing in stroma [10], upregulated by
DKK3 silencing in prostate epithelial cells (MMP2) [15]
and induced by Dkk-3 in endothelial cells (VEGFA) [20]. In
addition, since RWPE-1 cell cultures contain a stem/pro-
genitor cell population [21] and Dkk-3 promotes differ-
entiation of embryonic stem cells [22], we examined the
stem cell genes SOX2, OCT4 (POU5F1), and NANOG. We
also measured the expression of s-SHIP, which encodes an
isoform of SHIP1 (SH2-containing Inositol 5ʹ-Phosphatase)
that lacks the N-terminal domain [23] and is upregulated in
RWPE-1 stem/progenitor cells [24] and ALDH1A1, a
prostate cancer stem cell marker that may be a myoﬁbro-
blast marker in prostate stroma [25, 26]. In RWPE-1 cells,
DKK3 silencing increased MMP2 expression, as previously
observed [15]. It also increased s-SHIP expression and
showed trends for increasing expression of ACTG2,
ANGPT1, OCT4, and NANOG, whereas it reduced expres-
sion of SOX2 (Fig. 3a). DKK3 silencing in WPMY-1 cells
also reduced SOX2 expression (Fig. 3b). In addition, there
were reductions in ALDH1A1, SOX2, NANOG, ACTG2, and
s-SHIP (Fig. 3b). Thus, DKK3 silencing can have similar
(SOX2) and opposite (s-SHIP) effects on gene expression in
prostate stromal and epithelial cells.
To further explore the effect of DKK3 silencing on s-
SHIP, cells were transfected with GFP plasmids driven by
the mouse s-ship gene promoter [27], which has been used
to select for RWPE-1 stem/progenitor cells [24], or by a
control (CMV) promoter. Fluorescence activated cell sort-
ing (FACS) analysis indicated that DKK3 silencing
increased the proportion of s-ship-GFP-positive cells in
RWPE-1 cells (Fig. 3c and Supplementary Figure 5a and b),
consistent with increased expression of s-SHIP mRNA,
while there was no consistent effect in WPMY-1 cells.
RWPE-1 cells expressing s-SHIP show enhanced sphere-
forming capacity and resistance to arsenite-induced cell
death [24]. Consistent with this, DKK3 silencing increased
RWPE-1 prostasphere formation (Fig. 3d). This increase
was blocked by recombinant Dkk-3 (Fig. 3d) and by inhi-
bition of SHIP1 (Fig. 3e) at a dose that did not affect
RWPE-1 cell viability (Supplementary Figure 5c). In
addition, DKK3 silencing increased RWPE-1 cell clono-
genicity in colony formation assays (Fig. 3f) and increased
resistance of RWPE-1 cells to arsenite-induced cell death
(Fig. 3g). Thus, DKK3 silencing in RWPE-1 cells increases
prostate epithelial stem/progenitor cell properties that are
consistent with the observed increase in the expression of s-
SHIP.
TGF-β has been reported to inhibit ALDH1A1 expression
in primary prostate stromal cells [25, 26]. To test whether
this was also the case in WPMY-1 cells and to test whether
other genes affected by DKK3 silencing in WPMY-1 cells
are TGF-β-regulated, experiments were carried out in cells
treated with TGF-β or SB431542. In control WPMY-1
cells, ALDH1A1 expression was reduced by TGF-β treat-
ment and showed a trend for increase in SB431542-treated
cells (Fig. 3h). TGF-β also reduced SOX2 and s-SHIP.
However, SB431542 reduced SOX2 and ACTG2 and did
not affect s-SHIP. SB431542 also reduced DKK3 expres-
sion, which may have effects on expression of genes
regulated by DKK3. Examination of these genes in
shDKK3 WPMY-1 cells (Fig. 3i) found that ALDH1A1
expression was further reduced by TGF-β treatment and
showed a trend for an increase with SB431542, as seen in
control WPMY-1 cells. In contrast, TGF-β did not affect
expression of SOX2 or s-SHIP. However, these genes were
already expressed at very low levels in shDKK3 WPMY-1
cells. These results suggest that DKK3 silencing has an
impact on the expression of TGF-β-repressed genes in
WPMY-1 cells.
Taken together, our observations indicate that
DKK3 silencing has cell-type-speciﬁc effects in RWPE-1
and WPMY-1 cells that reﬂect alterations in the stem/pro-
genitor cell phenotype of RWPE-1 cells and, in part, on
TGF-β signaling in WPMY-1 cells.
WPMY-1 cell-conditioned media restore normal
acinar morphogenesis in a Dkk-3-dependent
manner
DKK3 silencing disrupts the ability of prostate epithelial
cells to form acini in 3D cultures, an effect that can be
rescued by inhibition of TGF-β/Smad signaling [7]. To
determine the effects of stromal Dkk-3 on acinar morpho-
genesis, we treated RWPE-1 cells with conditioned media
(CM) collected from control and DKK3-silenced WPMY-
1 cells cultured in RWPE-1 cell media for 48 h and carried
out acinar morphogenesis assays, scoring for normal, not-
ched, and deformed acini (Fig. 4a). shDKK3 RWPE-1 (sh6)
cells mostly formed notched and deformed acini in control
medium (Fig. 4b), as previously observed [7]. Addition of
parental WPMY-1 cell CM increased the number of normal
acini, compared to control, whereas CM from shDKK3
WPMY-1 (Wsh8) cells had no signiﬁcant effects (Fig. 4b).
Similar results were obtained using CM from shCTRL
(NPSM) and shDKK3 (Wsh7) WPMY-1 cells (Supple-
mentary Figure 6a) and using a second shDKK3 RWPE-1
cell line (sh30) (Supplementary Figure 6b). Thus, WPMY-1
cell CM restore normal acinar morphogenesis in a Dkk-3-
dependent manner.
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To determine whether stromal cells also have a general
effect on acinar morphogenesis, experiments were repeated
using RWPE-1 cells, which express Dkk-3 and form mostly
normal acini [7]. Compared to medium alone, WPMY-1
cell CM slightly improved acinar morphogenesis of RWPE-
1 cells, whereas shDKK3 WPMY-1 cell CM reduced it
(Fig. 4c). Similar results were obtained when comparing
shCTRL (NPSM) and shDKK3 (Wsh7) WPMY-1 cell CM
treatment of shCTRL (NS14) RWPE-1 cells (Supplemen-
tary Figure 6c). These results suggest that shDKK3 WPMY-
1 cell CM contains a factor that disrupts acinar morpho-
genesis. Acinar morphogenesis can be disrupted by EGF-
induced RWPE-1 cell proliferation [28]. We therefore car-
ried out co-culture assays to determine whether WPMY-1
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cells secrete factors affecting RWPE-1 cell proliferation.
Compared with medium alone, co-culture with shCTRL
WPMY-1 cells did not affect RWPE-1 cell proliferation. In
contrast, co-culture with shDKK3 WPMY-1 cells increased
RWPE-1 cell proliferation (Fig. 4d). These results suggest
that DKK3-silenced WPMY-1 cells secrete a factor that
increases RWPE-1 cell proliferation that might account for
the disruption of acinar morphogenesis by DKK3-silenced
WPMY-1 cell CM.
DKK3-silenced WPMY-1 cell CM increases prostate
cancer cell invasion
Dkk-3 inhibits the invasion of PC3 prostate cancer cells [7].
In order to determine the effects of stromal Dkk-3 on cell
invasion, PC3 cells were cultured in the presence of CM
from control and DKK3-silenced WPMY-1 cells. PC3 cell
invasion was signiﬁcantly higher in the presence of CM
from shDKK3 (Wsh8) WPMY-1 cells, compared to CM
from parental WPMY-1 cells (Fig. 4e). Similar results were
observed when comparing CM from shDKK3 (Wsh7) and
shCTRL (NPSM) WPMY-1 cell CM (Supplementary Fig-
ure 7a). WPMY-1 cell CM did not signiﬁcantly affect PC3
cell invasion, compared to medium alone (Supplementary
Figure 7b). These results are consistent with a model in
which the loss of Dkk-3 in stromal cells leads to the acti-
vation or secretion of factors that promote prostate cancer
cell invasion. Given the trend for increased MMP2 in
shDKK3 WPMY-1 cell CM (Supplementary Figure 4a and
b), we tested the effects of the MMP2 inhibitor ARP100.
ARP100 did not affect invasion in the presence of WPMY-1
CM but it reduced PC3 cell invasion in the presence of
shDKK3 WPMY-1 cell CM (Fig. 4f), consistent with
MMP2 activity playing a role in the increase in invasion
observed in the presence of DKK3-silenced WPMY-1 cell
CM.
Identiﬁcation of TGFBI and ECM-1 as secreted
proteins affected by DKK3-silencing in WPMY-1 and
RWPE-1 cells
To identify proteins involved in the response to Dkk-3, CM
from control and DKK3-silenced WPMY-1 and RWPE-1
cells were compared using an antibody array (Supplemen-
tary Figure 8). Two proteins affected by DKK3 silencing,
TGFBI and ECM1, were chosen for further study. Western
blotting and q-PCR were carried out to validate the antibody
array results. TGFBI was detected as a doublet at 68-70 kDa
(Fig. 5a), the reported size of TGFBI, and was more
abundant in CM from DKK3-silenced WPMY-1 cells than
control cells (Fig. 5b). DKK3 silencing did not affect
TGFBI mRNA levels in WPMY-1 cells (Fig. 5c). There
were also higher levels of TGFBI in CM from DKK3-
silenced RWPE-1 cell than in control cell CM (Fig. 5d, e).
In contrast to WPMY-1 cells, TGFBI mRNA levels were
higher in DKK3-silenced cells than in control RWPE-1 cells
(Fig. 5f). ECM-1 was detected as a protein of 85 kDa (Fig.
5g), the reported size of ECM-1, and was lower in DKK3-
silenced WPMY-1 cell CM than in control cell CM (Fig.
5h). DKK3 silencing did not affect ECM1 mRNA levels
(Fig. 5i). In contrast to WPMY-1 cells, ECM-1 levels were
higher in DKK3-silenced RWPE-1 cell CM than in control
RWPE-1 CM (Fig. 5j, k). Again, there was no effect on
ECM1 mRNA levels (Fig. 5l). In summary, DKK3 silencing
increased TGFBI levels in both WPMY-1 and RWPE-1
cells CM, whereas it had opposite effects on the levels of
ECM-1, increasing it in RWPE-1 cell CM and reducing it in
WPMY-1 cell CM.
TGFBI and ECM-1 have opposite effects on acinar
morphogenesis and PC3 cell invasion
In order to determine the possible functions of TGFBI and
ECM-1, we examined their effects on acinar morphogen-
esis. Cells were plated for acinar morphogenesis assays and
treated with media containing recombinant puriﬁed TGFBI
or ECM-1 at concentrations that we had determined to be
similar to those found in cell CM. Acinar morphogenesis of
DKK3-silenced RWPE-1 cells was not affected by addition
of TGFBI but was signiﬁcantly improved by addition of
Fig. 3 Contrasting effects of DKK3 gene silencing on gene expression
in prostate stromal and epithelial cells. a q-RT-PCR analysis of the
expression of the indicated genes in shCTRL (NS11) and shDKK3
(sh6) RWPE-1 cells, n= 3 or 2 (OCT4, VEGF). b q-RT-PCR analysis
of the expression of the indicated genes in shCTRL (PSM2/3) and
shDKK3 (Wsh7/8) WPMY-1 cells; n= 3 or 6 (SOX2)); error bars
show SD, *p < 0.05 compared to shCTRL. c Graph showing relative
number of GFP-positive cells upon transfection with s-SHIP-GFP,
compared to transfection with CMV-GFP, normalized to shCTRL
(NS11). d Graph showing mean numbers of prostaspheres for shCTRL
(NS11) and shDKK3 (sh6) RWPE-1 cells cultured for 7 days, either
untreated or in the presence of 50 or 100 ng/ml recombinant Dkk-3;
error bars show SD, *p < 0.05, n= 3. e Graph showing mean numbers
of prostaspheres for shCTRL (NS11) and shDKK3 (sh6) RWPE-1
cells cultured for 7 days, either untreated or in the presence of 100 nM
SHIP1 inhibitor (K118); error bars show SD, n= 2. f Left: example of
stained colonies from colony formation assays carried out using
shCTRL (NS11) and shDKK3 (sh6) RWPE-1 cells plated for 10 days
and stained with crystal violet. Graph shows mean colony number,
relative to shCTRL, error bars show SD, n= 3, *p < 0.05. g Cell
viability assays using shCTRL (NS11) and shDKK3 (sh6) RWPE-1
cells cultured for 48 h either untreated (ut) or treated with the indicated
concentrations of sodium arsenite and stained with crystal violet.
Graph shows relative cell number, normalized to ut for each cell line,
error bars show SD; n= 3, p < 0.05 comparing shCTRL and shDKK3
at 20 μM arsenite. h, i q-RT-PCR analysis of the indicated genes,
showing average relative expression in shCTRL (PSM3) (h) and
shDKK3 (Wsh8) (i) WPMY-1 cells either untreated (ut) or treated with
10 ng/ml TGF-β1 or 1 μM SB431542 for 24 h; n= 3, *p < 0.05 by
Student’s t test
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shDKK3 (Wsh8) WPMY-1 cells, n= 3, *p < 0.01. Left, representative
photos of invaded cells stained with crystal violet. Similar results were
obtained using CM from shCTRL (NPSM) and shDKK3 (Wsh7) cells
(Supplementary Figure 7). f Cell invasion assays using PC3 cells
cultured with CM from shCTRL (NPSM) and shDKK3 (Wsh8)
WPMY-1 cells with or without the MMP2 inhibitor ARP100; n= 3,
***p ≤ 0.001. Left: representative photos of invaded cells stained with
crystal violet. Scale bars 100 μm
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Fig. 5 Effects of DKK3 silencing on TGFBI and ECM-1 protein and
mRNA levels in WPMY-1 and RWPE-1 cells. a Western blots of CM
from equal numbers of shCTRL (PSM2) and shDKK3 (Wsh8)
WPMY-1 cells cultured in serum-free medium for 48 h were probed
for TGFBI; a Coomassie Blue (CB)-stained gel of samples run in
parallel was used as a loading control. b Densitometry analysis of
TGFBI in CM; graph shows average intensity normalized to PSM2,
error bars show SD, **p < 0.01, n= 5. c q-RT-PCR analysis of TGFBI
mRNA levels, relative to 36B4, in shCTRL (PSM2/PSM3) and
shDKK3 (Wsh7/Wsh8) WPMY-1 cells; error bars show SD. d
Western blots of CM from equal numbers of shCTRL (NS11) and
shDKK3 (sh6) RWPE-1 cells cultured in serum-free medium for 48 h
were probed for TGFBI; a CB-stained gel of samples run in parallel
was used as a loading control. e Densitometry analysis of TGFBI in
CM; graph shows average intensity normalized to NS11, error bars
show SD, **p < 0.01, n= 3. f q-RT-PCR analysis of TGFBI mRNA
levels, relative to 36B4, in shCTRL (NS11) and shDKK3 (sh6)
RWPE-1 cells; error bars show SD, n= 3, *p < 0.05. g–l ECM-1
protein and ECM1 mRNA levels were analyzed as in a–f; h **p <
0.01, n= 6, k *p < 0.05, n= 3
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ECM-1, which increased the number of normal acini and
reduced the number of deformed acini (Fig. 6a). In contrast,
ECM-1 did not affect acinar morphogenesis of control
RWPE-1 cells, whereas addition of TGFBI showed trends
for reducing the number of normal acini and increasing the
number of deformed acini (Fig. 6b).
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Since DKK3-silenced WPMY-1 cell CM increased PC3
cell invasion and contained more TGFBI and less ECM-1
than control cell CM, we hypothesized that exogenous
TGFBI and/or ECM-1 would affect PC3 cell invasion. PC3
cell invasion assays were therefore carried out in control
medium or media containing recombinant TGFBI, ECM-1,
or both proteins together (Fig. 6c). Compared to control,
TGFBI signiﬁcantly increased PC3 cell invasion, while
ECM-1 had no effect. However, ECM-1 inhibited TGFBI-
promoted cell invasion. There were no effects of either
protein on cell proliferation (results not shown). To deter-
mine if these effects could be observed in another metastatic
prostate cancer cell line, experiments were carried out using
C4-2B cells, a metastatic androgen-insensitive derivative of
LNCaP [29]. Similar to PC3 cells, C4-2B cell invasion was
increased by TGFBI treatment and this response was
inhibited by ECM-1 (Fig. 6d). Given the recent report
linking androgen signaling to TGFBI [30], experiments
were also carried out using enzalutamide-resistant C4-2B
cells (C4-2B MDVR). In contrast to PC3 and C4-2B, C4-
2B MDVR cell invasion was not signiﬁcantly affected by
TGFBI or ECM-1 (Fig. 6e). In summary, in the contexts of
prostate epithelial cell acinar morphogenesis and prostate
cancer cell invasion, TGFBI and ECM-1 have tumor-
promoting and tumor-suppressing functions, respectively.
The improvement in RWPE-1 acinar morphogenesis and
the inhibition of TGFBI-induced PC3 and C4-2B cell
invasion by exogenous ECM-1 suggests that increased
expression of ECM-1 in prostate cancer may be beneﬁcial
to patients, whereas the opposite may be true for TGFBI.
The lack of a signiﬁcant effect of either TGFBI or ECM-1
on invasion of enzalutamide-resistant C4-2B cells suggests
that the cellular response to these proteins may be altered in
treatment-resistant cells.
Correlations among the expression of Dkk-3, TGFBI,
and ECM-1 in patient tumors
In order to determine whether links between Dkk-3, TGFBI,
and ECM-1 could also be found in patient tumors, we
compared their expression levels by immunohistochemistry.
The scoring system used is shown in Supplementary Fig-
ures 9 and 10. TGFBI was more prevalent in cancer than in
benign epithelium and was found at lower levels in tumor
stroma than in benign stroma (Fig. 7a, b). Comparison of
TGFBI and Dkk-3 staining in cancer found high levels of
TGFBI in some tumors that expressed low levels of Dkk-3
(Fig. 7c), suggesting an inverse correlation. Statistical
analysis conﬁrmed this in low Gleason score tumors but not
in cancer stroma or benign tissue (Table 1). ECM-1 staining
was also higher in tumor epithelium than in benign epi-
thelium (Fig. 7d, e). There was no correlation between Dkk-
3 and ECM-1 in cancer, although there were correlations in
tumor stroma (Table 1).
To determine whether DKK3, TGFBI, and ECM1 mRNA
expression is associated with prostate cancer patient survi-
val, we used PROGgene (http://www.compbio.iupui.edu/
proggene) [31, 32] and the Prostate cancer dataset
GSE70768 [33]. Correlation of gene expression with
respect to relapse-free survival of prostate cancer patients
(n= 110) was analyzed by taking the median gene
expression value for each gene and then dividing patients
into high (above the median) and low (below the median).
Relapse-free survival was higher in patients with high
DKK3 expression than in patients with low DKK3 expres-
sion (Supplementary Figure 11a). High expression of ECM1
showed a trend for association with relapse-free survival (p
= 0.17, not shown), and this was signiﬁcant in a second
dataset (GSE70769; n= 91) (Supplementary Figure 11b).
There were no signiﬁcant differences in patient survival
with respect to TGFBI expression (Supplementary Figure
11c). These results are consistent with Dkk-3 and ECM-1
playing a protective role in prostate cancer.
Discussion
Several studies have reported downregulation of Dkk-3 in
prostate cancer [5]. Some of these also noted expression of
Dkk-3 in prostate cancer stroma [3, 6], but the relevance of
stromal Dkk-3 to prostate cancer was not examined. Given
the tumor-inhibitory properties of Dkk-3, we hypothesized
that the stromal expression of Dkk-3 is protective and may
prevent prostate cancer initiation or progression. Consistent
with this, examination of Dkk-3 expression in prostate
stroma in benign and tumor sections revealed a signiﬁcant
reduction in the levels of Dkk-3 in tumor stroma, compared
to that in stroma of benign tissue. To study the function of
stromal Dkk-3, we used WPMY-1 prostate stromal cells as
a model system. WPMY-1 cells are derived from benign
prostate stroma and their expression proﬁle indicates that
they are myoﬁbroblasts [34], the major cell type of reactive
stroma in well-differentiated foci of prostate cancer [1].
WPMY-1 cells secreted a high level of Dkk-3 that was
Fig. 6 TGFBI and ECM-1 have opposite effects on acinar morpho-
genesis and PC3 cell invasion. a Acinar morphogenesis assays for
shDKK3 (sh6) RWPE-1 cells cultured in media only (control) or with
ECM-1 (100 ng/ml) or TGFBI (1 μg/ml) for 7 days; error bars show
SD, *p < 0.05, **p < 0.01, n= 4. b Acinar morphogenesis assays for
shCTRL (NS11) RWPE-1 cells cultured as in a. c Invasion assays for
PC3 cells plated in triplicate wells for 24 h in serum-free RPMI with
PBS (Control) or with TGFBI (1 μg/ml), ECM-1 (100 ng/ml) or both
TGFBI and ECM-1. Left, example photos of invaded cells, right,
graph showing average number of invaded cells, normalized to con-
trol, error bars show SD, n= 3, **p < 0.01 by ANOVA; scale bars
100 μm. d, e Invasion assays for C4-2B cells (d) and enzalutamide-
resistant C4-2B (MDVR) cells (e) treated as in c
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further increased by TGF-β treatment. This suggests that
there may be a negative feedback loop in which down-
regulation of Dkk-3 activates TGF-β/Smad signaling,
leading to auto-induction of TGF-β1 [35], increased Dkk-3
secretion and subsequent inhibition of TGF-β signaling.
DKK3 silencing increased TGFβ/Smad-dependent tran-
scription both in WPMY-1 and RWPE-1 cells but there
were differences. DKK3 silencing increased Smad3 phos-
phorylation in WPMY-1 cells, whereas it increases Smad2
phosphorylation in RWPE-1 cells. Smad3 also plays a role
Fig. 7 Analysis of TGFBI and
ECM-1 in prostate cancer
patients. a Statistical analysis of
TGFBI expression in benign
prostate and prostate cancer; b
Benign and tumor sections from
a patient stained for TGFBI. c
Tumor sections from two
patients stained for TGFBI and
Dkk-3; scale bars 65 µm. d
Statistical analysis of ECM-1
expression in benign prostate
and prostate cancer. e Example
of a patient tumor with increased
ECM-1 in cancer, compared to
in benign epithelium. Benign
and cancer sections from the
same patient were stained for
ECM-1, SMA, and pan-CK;
scale bars 84 µm. Gl Gleason,
PCaE prostate cancer
epithelium, BS benign stroma,
PCaS prostate cancer stroma, BE
benign epithelium; Chi Sq. Chi
square Yates correction, Fisher,
Fisher’s Exact test, two-sided
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in the response to Dkk-3 in RWPE-1 cells, however, as the
Smad3 inhibitor SIS3 rescues acinar morphogenesis in
DKK3-silenced RWPE-1 cells [7]. Common targets of Dkk-
3 in WPMY-1 and RWPE-1 cells include TGFBI and
possibly MMP2. TGFBI and MMP2 are both TGF-β target
genes that are upregulated by DKK3 silencing in RWPE-1
cells [10]. In WPMY-1 cells, TGFBI expression is also
increased by TGF-β and reduced by SB431542 treatment
(Supplementary Figure 12c), and these responses are
blunted in shDKK3 WMPY-1 cells (Supplementary Figure
12d). DKK3 silencing did not appear to affect TGFBI or
MMP2 gene expression in WPMY-1 cells, although it
increased TGFBI protein levels and showed a trend for
increasing MMP2 protein levels. Both TGFBI and MMP2
are highly expressed in WPMY-1 cells, which may make it
difﬁcult to observe increases at the mRNA level. Alter-
natively, DKK3 silencing may increase MMP2 activity,
rather than expression. The relevance of increased MMP2
activity for prostate cancer cell invasion is underlined by the
ability of the MMP2 inhibitor ARP100 to reduce the pro-
invasive effects of DKK3-silenced WPMY-1 CM in PC3
cells. Dkk-3 is itself a proteolytic target of MMP2 [36],
providing further possibilities for functional interaction. The
function of TGFBI in prostate stromal cells remains to be
determined. Treatment of WPMY-1 cells with recombinant
TGFBI for 24 h had minimal effects on the expression of
genes altered by DKK3 silencing (Supplementary Figures
12a and b), although it did reduce ALDH1A1 expression in
shCTRL WPMY-1 cells. The reduction (29%) was weaker
than those of TGF-β1 (79%) or DKK3 silencing (91%),
suggesting that TGFBI alone is not responsible for the
reduced expression of ALDH1A1 in DKK3-silenced cells.
In addition to these common effects of DKK3 silencing
in RWPE-1 and WPMY-1 cells, we observed opposite
effects on s-SHIP expression, suggesting that Dkk-3 plays
cell-type-speciﬁc roles that relate to cell differentiation.
DKK3 silencing also had opposite effects on ECM-1 protein
levels. These differential effects of DKK3 silencing may
reﬂect cell type-speciﬁc differences in TGF-β signaling,
differential glycosylation or proteolytic processing of Dkk-3
[37, 38], or the expression of cell-type-speciﬁc Dkk-3
receptors. Mammalian receptors for Dkk-3 have yet to be
identiﬁed, but zebraﬁsh Dkk3a, which is 42% identical to
human Dkk-3, binds an α6 integrin [39, 40]. Although the
Fig. 7 (Continued)
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results of our experiments using WPMY-1 cell CM are
more consistent with Dkk-3 acting extracellularly or via
cell-surface receptors, some studies suggest Dkk-3 also acts
intracellularly [5]. Recently, an alternative start site in the
mouse Dkk3 promoter was identiﬁed that produces an
intracellular form of Dkk-3 (Dkk3b) that inhibits cell pro-
liferation by binding to β-catenin in a complex with β-TrCP
[41]. However, it is not known if Dkk3b exists in human
cells.
TGFBI protein levels were signiﬁcantly higher in pros-
tate cancer than in benign prostate. There was an inverse
correlation of TGFBI and Dkk-3 expression in prostate
cancer, consistent with the increased levels of TGFBI
observed upon DKK3 silencing in RWPE-1 cells. In con-
trast, TGFBI expression was lower in tumor stroma, com-
pared to that in benign stroma and did not show an inverse
correlation with Dkk-3, in fact there was a trend for a
positive correlation. The inverse correlation between
TGFBI and Dkk-3 in cancer was only observed in low
Gleason score tumors, suggesting that regulation of TGFBI
by Dkk-3 is less important in more advanced prostate
cancer. This would be consistent with the correlation of
high DKK3 but not low TGFBI expression with relapse-free
survival in patients. A comparison of TGFBI and Dkk-3 by
immunohistochemistry in a larger cohort of patients will be
required to determine if this is the case. TGFBI binds to
type I, II, and IV collagens and integrins to regulate cell
adhesion and migration [42]. Expression of TGFBI in
prostate cancer is repressed by promoter methylation [43]
and by miR-675, which inhibits prostate cancer migration
[44]. In addition, TGFBI expression is repressed by the
androgen-regulated transcription factor SPDEF [30].
Androgen deprivation was found to increase TGFBI levels
and TGFBI knockdown suppressed prostate cancer cell
migration and inhibited tumor growth and metastasis [30].
We found that TGFBI increased the invasion of PC3 and
C4-2B cells, but not of enzalutamide-resistant C4-2B
MDVR cells. The reason for this is not known but it could
reﬂect changes in the expression of TGFBI receptors. We
noted that C4-2B cells had a higher capacity for invasion
than C4-2B MDVR cells (VMG, unpublished results).
Moreover, endogenous TGFBI mRNA expression was
similarly low in C4-2B and C4-2B MDVR cells (Supple-
mentary Figures 12e and f), suggesting that TGFBI does not
play a role in enzalutamide resistance in this cell model.
ECM-1 was the other major protein in CM affected by
DKK3 silencing. DKK3 silencing had no effect on ECM1
mRNA levels, suggesting that Dkk-3 affects ECM-1 protein
stability or secretion. ECM-1 was difﬁcult to detect in
RWPE-1 cell extracts, while in WPMY-1 cell extracts it
was not signiﬁcantly affected by DKK3 silencing, sug-
gesting that most ECM-1 is secreted and that the increase of
ECM-1 in CM is a result of increased secretion or stability.
ECM-1 associates with several extracellular proteins,
including MMP9, which it inhibits [45], and perlecan.
ECM-1 and perlecan form a network of basement mem-
brane proteins that also contains collagen IV and laminin
[45, 46]. ECM-1 is overexpressed in many types of cancer
[47] and in most cases it has a tumor-promoting effect,
correlating with increased metastasis and poor prognosis.
However, in hepatocellular cancer, ECM1 gene silencing
increases anchorage-independent growth [48]. We found
that ECM-1 was more highly expressed in prostate cancer
than in benign prostate epithelium. However, there was a
positive correlation of Dkk-3 and ECM-1 in cancer stroma,
and ECM1 gene expression correlated with increased
relapse-free survival of prostate cancer patients, suggesting
ECM-1 has a tumor-inhibitory function. The correlation of
Dkk-3 and ECM-1 in cancer stroma might reﬂect a situation
where the loss of Dkk-3 in tumor cells leads to increased
expression of stromal Dkk-3 and ECM-1 in a homeostatic
response that prevents tumor progression. Consistent with
this, ECM-1 increased normal acinar morphogenesis in
RWPE-1 cells and inhibited the pro-invasive activity of
TGFBI in PC3 and C4-2B cells. It is not clear how ECM-1
inhibits TGFBI-induced invasion, but it may inhibit MMP
activity [45] or compete with TGFBI for integrin binding.
TGFBI binds to integrins via an RGD motif and ECM-1 can
compete with RGD peptides to bind αv integrins and block
Table 1 Correlation of Dkk-3 with TGFBI and ECM-1 in patient
tumors
Comparison Correlation coefﬁcient p
Dkk-3 PCaE vs. TGFBI PCaE −0.305 0.0037
Gl. ≥ 43 −0.1794 0.437
Gl. ≤ 34 −0.2986 0.014
Dkk-3 PCaCS vs. TGFBI PCaCS 0.2028 0.057
Gl. ≥ 43 −0.1077 0.642
Gl. ≤ 34 0.0464 0.709
Dkk-3 BE vs. TGFBI BE −0.0638 0.553
Dkk-3 BS vs. TGFBI BS 0.1792 0.093
ECM1 PCaE vs. Dkk-3 PCaE 0.069 0.58
ECM1 PCaS vs. Dkk-3 PCaS 0.396 0.001
Gl. ≥ 43 0.177 0.48
Gl. ≤ 34 0.514 0.0002
ECM-1 BS vs. Dkk-3 BS 0.009 0.942
ECM-1 BE vs. DKK3 BE 0.133 0.308
ECM-1 PCaE vs. TGFBI PCaE 0.239 0.052
ECM-1 PCaS vs. TGFBI PCaS 0.367 0.002
Gl. ≥ 43 0.433 0.072
Gl. ≤ 34 0.3445 0.018
ECM1 BE vs TGFBI BE −0.152 0.241
ECM1 BS vs. TGFBI BS 0.126 0.331
Numbers in bold highlight statistically signiﬁcant differences
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activation of latent TGF-β [49]. PC3 cells express integrin
αvβ6, which plays a role in their migration [50], so it is
possible that ECM-1 inhibits TGFBI-induced invasion by
blocking TGFBI-mediated integrin activation.
In conclusion, our results are consistent with a negative
feedback model that implicates Dkk-3 and TGF-β signaling
in the regulation of epithelial–stromal interactions taking
place during prostate cancer initiation and progression. In
this model, expression of Dkk-3 in the benign prostate
epithelium prevents aberrant activation of TGF-β signaling.
The epigenetic loss of DKK3 expression activates TGF-β
signaling, leading to increased expression of pro-invasive
factors, such as TGFBI and MMP2, which have the
potential to promote progression to cancer. However, acti-
vation of TGF-β signaling also leads to increased secretion
of stromal Dkk-3, which provides a ﬁrst line of defense. The
results of our WPMY-1 cell experiments indicate that
stromal Dkk-3 can attenuate prostate epithelial cell pro-
liferation, restore normal prostate epithelial architecture (as
reﬂected by the acinar morphogenesis assays) and inhibit
prostate cancer cell invasion. The loss of stromal Dkk-3 is
therefore predicted to lead to further disruption of prostate
architecture, increased proliferation and prostate cancer cell
invasion. The correlation of ECM-1 and Dkk-3 expression
in WPMY-1 cells, ECM-1 inhibition of TGFBI-dependent
prostate cancer cell invasion and the correlation of ECM1
and DKK3 expression with relapse-free survival, suggest
that ECM-1 also participates in the Dkk-3 defense
mechanism.
Materials and methods
Cell culture
WPMY-1 cells [34] (ATCC) were cultured in DMEM (Life
Technologies) with 10% FCS (First Link Ltd.) and anti-
biotics (100 units/ml penicillin and 100 μg/ml streptomycin,
Sigma). RWPE-1 (ATCC) and RWPE-1 shRNA cell lines
(NS11, NS14 expressing control shRNA, sh6 and sh30
expressing DKK3 shRNA) [7] were cultured in keratinocyte
serum-free medium (KSFM) supplemented with bovine
pituitary extract (BPE) and EGF (Thermo Fisher) and
antibiotics, with 0.75 μg/ml puromycin (Sigma) added to
shRNA-expressing cells. PC3 cells (ATCC) and C4-2B
cells (from Charlotte Bevan, Imperial College London),
were cultured in RPMI-1640 with Glutamax (Life Tech-
nologies), 10% FCS and antibiotics and were authenticated
by DNA proﬁling (Euroﬁns Genomics, Germany). All cells
were cultured at 37 °C and 5% CO2 and tested for myco-
plasma (Mycoplasma Detection Kit, Lonza) every
3 months. WPMY-1 cells were transfected with pSM2-
based shRNAmir plasmids [7] using Lipofectamine 2000
and selected in medium containing 1.5 μg/ml puromycin.
DKK3 shRNA cell lines were derived from single colonies
and control shRNA cells from pools of 20-50 colonies. Two
DKK3 shRNA clones (shDKK3 Wsh7 and Wsh8) and four
control shRNA lines (shCTRL PSM2, PSM3, NPSM) were
used for these studies. Enzalutamide-resistant C4-2B cells
(C4-2B MDVR) were generated by culturing C4-2B cells in
the presence of 20 μM enzalutamide (MDV3100) (Sell-
eckchem) for 2 weeks and then 10 μM MDV3100 for
3 months, after which they were maintained in the presence
of 10 μM MDV3100. Control cells were cultured in parallel
in the presence of an equal volume of carrier (DMSO).
Western blotting
Cells (2–4 × 105) were plated in duplicate wells of six-well
plates for 48 h prior to preparation of cell extracts. In some
experiments, media were changed to serum-free with or
without 10 ng/ml TGF-β (R&D Systems) for 24 h. CM were
centrifuged at 500 × g for 5 min and supernatants added to
an equal volume of 2× Laemmli buffer (Sigma). Cells were
lysed on ice in RIPA lysis buffer (0.5% Na deoxycholate,
1% Triton X-100, 20 mM Tris pH 8.0, 0.1% SDS, 100 mM
NaCl, 50 mM NaF, 1 mM EDTA), cOmplete™ EDTA-free
Protease Inhibitor Cocktail (Sigma) and PhosSTOP Phos-
phatase Inhibitor Cocktail (Sigma)). Lysates were incubated
for 15 min on ice, centrifuged at 15,000×g for 15 min at 4 °
C and added to an equal volume of 2× Laemmli buffer. To
determine the levels of TGFBI and ECM-1 in CM, 106 cells
per well were plated in six-well plates overnight and the
media changed to 1 ml of the appropriate serum-free media
(KSFM or DMEM, respectively) for 48 h, prior to collection
of CM. Samples were heated on a shaker for 3 min at 95 °C
prior to loading on 7.5 or 10% SDS polyacrylamide gels.
Transfer of proteins to PVDF membranes was carried out
using a semi-dry transfer apparatus (Bio-Rad). Membranes
were rinsed in TBST (Tris-buffered saline with 0.1% Tween
20) and incubated in blocking buffer (5% BSA in TBST) at
room temperature for 1 h. Primary antibodies (Supplemen-
tary Table 1) diluted in blocking buffer were added and
membranes were incubated on a rocker in a cold room
overnight. Membranes were washed at least three times for
5 min in TBST, incubated with HRP-conjugated donkey
secondary antibodies (1:10,000, Stratech Scientiﬁc Ltd) in
blocking buffer for 1 h, washed three times for 15 min and
incubated with ClarityTM ECL solution (Bio-Rad) for 5 min,
exposed to X-ray ﬁlm and developed using an OPTIMAX
ﬁlm processor.
RNA extraction, cDNA synthesis, and q-RT-PCR
Total RNA was extracted using PureLink RNA Mini Kit
(Life technologies). cDNA was synthesized from total RNA
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using Quantitect Reverse Transcription Kit (Qiagen)
according to manufacturer’s instructions. Gene expression
was determined by q-PCR using SYBR Green PCR Master
Mix (Bio-Rad) and a 7900HT Fast Real-Time PCR thermal
cycler (Applied Biosystems) as previously described [15].
The expression levels of target gene were normalized to an
endogenous reference gene (36B4) and the fold change, as a
measure of relative expression, was calculated using the
comparative CT (2–ΔΔCT) method [51]. The sequences of
the primers used are in Supplementary Table 2.
Fluorescence activated cell sorting
Cells were plated overnight in six-well plates (105 cells per
well) prior to transfection with plasmids encoding GFP
driven by a constitutive promoter (CMV) or the mouse s-
ship gene promoter (s-SHIP-GFP) [27] using Lipofectamine
Plus. After 24 h, transfected cells were washed in PBS,
trypsinized, centrifuged in FACS tubes at 500×g for 5 min
and resuspended in 500 μl 1% BSA in PBS with 7-Amino-
Actinomycin D (7-AAD) (Invitrogen) to identify non-viable
cells. FACS analysis was carried out using a FACS Aria
ﬂow cytometer (Becton Dickinson) and FACS Diva™
Software.
Acinar morphogenesis, colony formation, and
prostasphere assays
Acinar morphogenesis (AM) assays were carried out using a
previously published protocol [52] with modiﬁcations [4].
Brieﬂy, 2000 early passage RWPE-1 cell lines (80–85%
conﬂuent) were suspended in assay media (KSFM with
5 ng/ml EGF, 2% bovine calf serum and 2% basement
membrane extract (Cultrex phenol red-free BME, Bio-
Techne Ltd)) and plated in eight-well microslides (Nunc)
coated with 40 μl BME per well. CM from control and
DKK3-silenced WPMY-1 cells cultured in parallel in assay
media for 48 h were collected, centrifuged, and used for AM
assays. The remainder was kept at 4 °C for subsequent
media changes every 2 days. AM was evaluated as descri-
bed in other studies [4, 7]. Five photos (×100 magniﬁcation)
per well were taken at days 4, 6, 7, and 8 using an Axiovert
S 100 microscope (Zeiss) and processed with MetaMorph
(Molecular Devices) or using an Eclipse TE2000-U
microscope (Nikon) and Image-Pro (Media Cybernetics
Inc.). The numbers of regular, notched and deformed acini
were counted using ImageJ software. Each experiment was
repeated in triplicate wells three or four times. Recombinant
human (rh) TGFBI (1 μg/ml) and rhECM-1 (100 ng/ml)
(R&D Systems) were added to acini every 2 days. Colony
formation assays were carried out by plating 200 RWPE-1
shCTRL (NS11) and shDKK3 (sh6) cells in triplicate in 12-
well plates for 10 days, changing media every 3 days. Cell
colonies were washed with PBS, stained for 20 min using
crystal violet (0.2% w/v crystal violet, 20% methanol, 0.4%
v/v paraformaldehyde in PBS) and washed again with PBS
prior to counting colonies by eye. Prostasphere assays were
carried out as previously described [53]. Brieﬂy, shCTRL
(NS11) or shDKK-3 (sh6) RWPE-1 cells were plated in
quadruplicate in 24-well ultra-low attachment plates
(Corning) at 125, 250, or 500 cells per well in DMEM/F-12
with GlutaMAX, antibiotics, B-27 Supplement (Thermo
Fisher), 10 ng/ml EGF, and 2 ng/ml bFGF (PeproTech). The
SHIP1 inhibitor K118 (Tebu-Bio) was freshly dissolved in
water and used at the concentrations indicated. Images of
prostaspheres were captured by a camera connected to an
Olympus inverted microscope. The total numbers of spheres
formed and spheres larger than 125 nm in diameter were
evaluated 7 days after plating.
Gene reporter assays
Gene reporter assays were carried out using pGL3-
CAGA12-luc (CAGA-luc), which encodes the luciferase
gene fused to 12 repeats of a Smad-binding element [54]
and pRL-TK (Promega) as a control. 200,000 cells per well
of a 12-well plate were cultured overnight in media without
antibiotics and transfected with 100 ng pRL-TK and 400 ng
CAGA-luc per well using Lipofectamine LTX with Plus
reagent. After 4–5 h, 0.5 ml growth medium was added to
each well together with 0.5 ml of medium containing
SB431542 (Sigma), SB525334 (Bio-Techne), or an equal
volume of vehicle (DMSO). After 24 h, cells were lysed in
200 μl per well passive lysis buffer (Promega), frozen and
thawed, centrifuged at 15,000×g for 1 min and subjected to
luciferase assays using the Dual-Glo® Luciferase assay kit
(Promega) or Luciferase Assay Kit (PJK, Germany),
according to manufacturers’ instructions, on a Vector
luminometer.
Cell proliferation assays
Cells plated in ﬂasks with 10% FCS DMEM and antibiotics
were grown to 80% conﬂuence prior to plating for pro-
liferation assays. Eight thousand cells per well were plated
in triplicate in 24-well plates and incubated at 37 °C. Cells
were ﬁxed with ice-cold MeOH and stained with 0.2%
crystal violet in 20% MeOH at days 1, 3, 5, and 7. Stained
cells were solubilized in 10% acetic acid and 100 μl per well
was transferred in duplicate to a 96-well plate for mea-
surement of absorbance at 595 nm using an OptiMax plate
reader. For co-culture proliferation assays, 50,000 sh30 or
sh6 cells in KSFM with 5 ng/ml EGF, 2% bovine calf
serum, and 600 μl of 1% BME were plated on 0.4 μm pore
inserts in six-well plates. The wells below the inserts were
plated with 100,000 WPMY-1 cells in 10% FCS DMEM.
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Cells were incubated for 48 h at 37 °C and ﬁxed using cold
MeOH, stained with 0.2% crystal violet and visualized and
counted.
Invasion and migration assays
PC3 cells starved for 24 h in serum-free RPMI were placed
on 8 μm pore Polycarbonate Membrane Transwell inserts in
24-well plates. For invasion assays, inserts were either pre-
coated with 1% BME in serum free RPMI and allowed to
dry overnight or were carried out using 24-well Corning
BioCoat Matrigel Invasion Chambers (SLS Ltd., UK). The
assay media contained CM collected after 48 h of serum-
free culture of control and DKK3-silenced WPMY-1 cells.
PC3 cells were added to the inserts in duplicate in 200 μl
serum-free CM, and 800 μl of 10% FCS RPMI was added to
the wells below. After 48 h, invaded cells were ﬁxed in cold
MeOH, stained with 0.2% crystal violet in 20% MeOH and
at least ﬁve pictures were taken per insert at ×100 magni-
ﬁcation using an Eclipse TE2000-U microscope (Nikon)
and Image-Pro (QImaging, Surrey, BC, Canada). Image J
software was used to count the numbers of invaded cells.
Invasion and migration were also assessed after treatment
with 100 nM ARP100 (Santa Cruz Biotechnology). In
parallel, PC3 cells were seeded directly in 24-well plates,
treated in the same way as the cells used for invasion and
migration assays, stained with crystal violet and the num-
bers used to normalize the migration and invasion data for
cell number. To determine the impact of TGFBI and ECM-1
on PC3 cell invasion, 10,000 PC3 cells were plated in tri-
plicate for 24 h and treated with serum-free RPMI alone or
with 1 μg/ml rhTGFBI, 100 ng/ml rhECM-1 or both. C4-2B
and C4-2BR cell invasion assays were carried out as for
PC3 cells, except for the numbers of cells plated (50,000)
and the invasion time (24 h).
Proteome proﬁler array
Proteome proﬁling was carried out using the Human Solu-
ble Receptor Array Kit (ARY012, R&D Systems). Prior to
harvesting CM, 106 cells were plated in 60 mm dishes in
10% FCS DMEM for 24 h. Five photos per plate were taken
using a TE2000-U microscope (Nikon) and cells were
counted using Image J. Cells were then washed gently in
serum-free DMEM and incubated in serum-free DMEM
(~3 ml) with the exact volume adjusted to cell number.
After 24 h, CM were collected, centrifuged, and stored at
−80 °C. The levels of Dkk-3 in CM were determined by
western blotting prior to use and to ensure the absence of
intracellular proteins (by blotting for Smad3). Arrays were
probed according to the manufacturer’s instructions using
1 ml of CM. Two experiments were carried with indepen-
dently generated samples of CM. The results were analyzed
by densitometry of multiple exposures of the arrays to X-
ray ﬁlm.
Histochemistry
Tissue arrays (TMAs) with samples from a total of 99
Prostate cancer patients on six arrays were provided by the
Imperial Cancer Biomarker Resource Centre (ICBRC) after
approval from Imperial CRUK Steering Committee (Tissue
Bank application number Project R15043), following
patient consent and approval from the local research ethics
committee (ref: ICHTB HTA; licence: 12275; REC Wales
approval: 12/WA/0196). A total of four sections were
provided per patient, two with benign tissue and two with
cancer. Nine cores did not contain cancer and were exclu-
ded from the analysis. Adjacent or near-adjacent sections of
the TMAs were stained for SMA, vimentin, Dkk-3, pan-
cytokeratin (CK), TGFBI, and ECM-1. Slides were incu-
bated in a dry oven at 60 °C for 1 h, dewaxed using His-
toclear 3 times for 10 min and hydrated by incubation in
100% EtOH twice for 1 min, 70% EtOH for 30 s and
immersion in dH20 for 5 min. Antigen retrieval was by
immersion in 10 mM Na citrate pH 6.0 in a small glass cup
and heating in a microwave oven at 560W for 8 (Dkk-3),
15 (TGFBI), or 10 (ECM-1) min, and cooling for 30 min.
Slides were washed three times in PBS for 5 min on a
rocking platform. Endogenous peroxidase was quenched by
immersion in 3% H2O2 for 5 min (ECM-1 for 3 min) and
washing three times in PBS for 5 min. Slides were incu-
bated in blocking buffer (Dkk-3 10% horse serum (HS) in
PBS, pan-cytokeratin 3% BSA in PBS, TGFBI and ECM-1
5% goat serum in PBS) for 20 min and incubated with
primary antibodies (Supplementary Table 1) in blocking
buffer overnight at 4 °C. Slides were washed three times in
PBS for 5 min, incubated with biotin-conjugated secondary
antibodies (1:200, Vector Laboratories) in blocking buffer
for 30 min at RT. Bound antibodies were detected using
Vectastain Elite ABC Standard kit (Vector Laboratories),
according to manufacturer’s instructions. Pictures were
taken using a Leica DM750 microscope. Staining intensities
were scored independently by two people (ZAS and RMK),
any divergences in scores were re-evaluated until consent
was found. Scoring for Dkk-3 was repeated by a histo-
pathologist (IZ). Each core was scored based on the staining
intensity as 0 (no staining), 1 (weak staining), 2 (moderate
staining), or 3 (strong staining, if present).
Statistical analysis
Results are presented as the mean ± standard deviation
(SD). All experiments were repeated at least three times.
Statistical evaluations were performed with GraphPad Prism
5.0 (GraphPad, La Jolla, CA, USA) using two-sided
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Student’s t test for single comparisons or one-way analysis
of variance (ANOVA) with post hoc Tukey for multiple
group comparisons. A two-tailed p value < 0.05 was con-
sidered to indicate statistical signiﬁcance. For TMA analy-
sis, patients were divided into low (0, 1) and high (2, 3)
expression and Gleason scores ≥ 4+ 3 and ≤ 3+ 4 and
analyzed by one-way v2 test, Chi-squared test with Yates
correction or Fisher’s exact test, two-sided, available on the
VassarStats website (http://vassarstats.net/). Correlation
analysis was calculated using Phi-correlations. Analyses
were performed using SPSS v16 (IBM Corp., Somers, NY,
USA) or MATLAB-MathWorks software. For multiple
comparisons in acinar morphogenesis assays, two-way
ANOVA and Tukey’s multiple comparison was done
using Graphpad Prism v6.
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